Buchumschlag

Adverse Effects Related to Paediatric Influenza Vaccination and Its Influence on Vaccination Acceptability. The FLUTETRA Study: A Survey Conducted in the Region of Murcia, Spain

Fuente: Wiley Open Access

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	Matilde Zornoza Moreno, Jaime Jesús Pérez Martín, María Cruz Gómez Moreno, María del Carmen Valcárcel Gómez, Marta Pérez Martínez, Francisca Isabel Tornel Miñarro
Format:	Artículo Open Access
Veröffentlicht:	Wiley 2024
Schlagworte:	Influenza and Other Respiratory Viruses
Online-Zugang:	Acceder al recurso
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge

Influenza Epidemiology and Vaccine Effectiveness Following Funded Influenza Vaccine in Queensland, Australia, 2022
von: Ashish C. Shrestha, et al.
Veröffentlicht: (2024)

Seasonal Influenza Vaccine 2021/2022 Provides Limited Cross Reactivity Against Contemporary Swine Influenza A Virus Strains in Spain
von: Paloma Encinas, et al.
Veröffentlicht: (2025)

Neurologic Complications of Influenza and Potential Protective Vaccine Effects
von: Ann R. Falsey
Veröffentlicht: (2025)

Influenza Vaccine Effectiveness in Australia During 2017–2019
von: Tanya Diefenbach‐Elstob, et al.
Veröffentlicht: (2025)

The Potential for Twice‐Annual Influenza Vaccination to Reduce Disease Burden
von: Shuyi Zhong, et al.
Veröffentlicht: (2025)

Meeting Report: Fourth Correlates of Protection for Next Generation Influenza Vaccines
von: Alina Tscherne, et al.
Veröffentlicht: (2026)

Burden of Influenza and Cost‐Effectiveness Analysis of Introduction of an Influenza Vaccination Programme Among Older Adults in India
von: Anand Krishnan, et al.
Veröffentlicht: (2026)

Human Immune Response to Influenza Neuraminidase After Vaccination: A Systematic Review
von: Vardhini Ganesh, et al.
Veröffentlicht: (2025)

Evaluating Bacillus Calmette–Guérin Polysaccharide Nucleic Acid as an Adjuvant for Influenza Vaccines in Mice
von: Sijing Yan, et al.
Veröffentlicht: (2025)

High‐Dose Quadrivalent Influenza Vaccine for Prevention of Cardiovascular and Respiratory Hospitalizations in Older Adults
von: Arto A. Palmu, et al.
Veröffentlicht: (2024)

Effectiveness of Influenza Vaccines and Duration of Protection Against Hospitalisation in England: 2022/2023 and 2023/2024 Seasons
von: Heather J. Whitaker, et al.
Veröffentlicht: (2025)

Interim 2023/2024 Season Influenza Vaccine Effectiveness in Primary and Secondary Care in the United Kingdom
von: Heather Whitaker, et al.
Veröffentlicht: (2024)

A Rapid Virus‐Free Method for Producing Influenza HA Immunogen Needed for Preparation of Influenza Vaccine Potency Antisera Reagents
von: Marcus Odin, et al.
Veröffentlicht: (2024)

Influenza Vaccine Effectiveness Against Symptomatic Influenza in Primary Care: A Test Negative Case Control Study Over Two Influenza Seasons 2022/2023 and 2023/2024 in Ireland
von: Louise Marron, et al.
Veröffentlicht: (2024)

Antiviral Prescription in Children With Influenza in US Emergency Departments: New Vaccine Surveillance Network (NVSN), 2016–2020
von: Tess Stopczynski, et al.
Veröffentlicht: (2025)

Influenza Vaccine Effectiveness Against Influenza A(H1N1)pdm09‐Associated Hospitalizations With SARI in Beijing, China, in the 2024–2025 Season
von: Chunna Ma, et al.
Veröffentlicht: (2026)

Home‐Based Testing as an Approach to Estimate Influenza Vaccine Effectiveness in South Africa, 2021–2022—A Pilot Study
von: Jocelyn Moyes, et al.
Veröffentlicht: (2024)

Comparative Effectiveness of Cell‐Based Versus Egg‐Based Influenza Vaccines in Prevention of Influenza Hospitalization During the 2022–2023 Season Among Adults 18–64 Years
von: Emily Rayens, et al.
Veröffentlicht: (2024)

Effectiveness of Influenza Vaccines in Italy in the 2024/2025 Season: A Nationwide, Test‐Negative Design Study Based on Surveillance Records
von: Daniel Cifo, et al.
Veröffentlicht: (2026)

COVID‐19 Hospitalizations, Vaccine Uptake, Vaccination Guidelines, and Vaccine Availability in Six Middle‐Income Countries and Areas in Europe, May 2022–April 2024
von: Erin Rachel Whitehouse, et al.
Veröffentlicht: (2025)

The Epidemiology, Phylogeny, and Strain Antigenicity of an Influenza A/H3N2 Virus Outbreak Among Vaccinated US Navy Midshipmen
von: Simon D. Pollett, et al.
Veröffentlicht: (2025)

Correction to “Effectiveness of Influenza Vaccines in Italy in the 2024/2025 Season: A Nationwide, Test‐Negative Design Study Based on Surveillance Records”
Veröffentlicht: (2026)

Early COVID‐19 XBB.1.5 Vaccine Effectiveness Against Hospitalisation Among Adults Targeted for Vaccination, VEBIS Hospital Network, Europe, October 2023–January 2024
von: Liliana Antunes, et al.
Veröffentlicht: (2024)

Targeting Respiratory Viruses: The Efficacy of Intranasal mRNA Vaccination in Generating Protective Mucosal and Systemic Immunity Against Influenza A (H1N1)
von: Sara Yahyaei, et al.
Veröffentlicht: (2025)

A Monoclonal Antibody ELISA–Based Assay for Measuring the Potency of Candidate H5 Clade 2.3.4.4b Pandemic Influenza Vaccines
von: Marcus Odin, et al.
Veröffentlicht: (2026)

Relative Effectiveness of High‐Dose vs. Standard‐Dose Influenza Vaccines in Preventing Hospitalizations: A National Retrospective Cohort Study in France, 2022/2023 Season
von: Hélène Bricout, et al.
Veröffentlicht: (2025)

Burden of Severe Disease Associated With Influenza, SARS‐CoV‐2 and RSV in Spain During the 2024–2025 Winter Season
von: Daniel Aguilar Figueroa, et al.
Veröffentlicht: (2025)

Evaluating Pilot Implementation of ‘PenCS Flu Topbar’ App in Medical Practices to Improve National Immunisation Program–Funded Seasonal Influenza Vaccination in Central Queensland, Australia
von: Gulam Khandaker, et al.
Veröffentlicht: (2024)

Influenza Vaccine Effectiveness During the 2023/2024 Season: A Test‐Negative Case–Control Study Among Emergency Hospital Admissions With Respiratory Conditions in Northern Ireland
von: Magda Bucholc, et al.
Veröffentlicht: (2025)

Immunogenicity and Safety of AS03‐Adjuvanted H7N9 Influenza Vaccine in Adults (18–64 and ≥65 Years): A Phase 1/2, Randomized, Placebo‐Controlled Trial
von: Andrew Hastie, et al.
Veröffentlicht: (2024)

Should We Vaccinate Healthcare Workers Against Respiratory Syncytial Virus?
von: Klinger Soares Faico‐Filho, et al.
Veröffentlicht: (2024)

An Overview of the H5N1 mRNA Vaccine Pipeline
von: Daniele Focosi, et al.
Veröffentlicht: (2025)

Correction to “An Overview of the H5N1 mRNA Vaccine Pipeline”
Veröffentlicht: (2026)

Rethinking Optimal Immunogens to Face SARS‐CoV‐2 Evolution Through Vaccination
von: Julià Blanco, et al.
Veröffentlicht: (2025)

Effectiveness of 2024/25 KP.2 Vaccine Against Outpatient COVID‐19 in Canada
von: Lea Separovic, et al.
Veröffentlicht: (2026)

COVID‐19 Vaccine Effectiveness Against Hospitalization in Older Adults, VEBIS Hospital Network, Europe, September 2024–May 2025
von: Madelyn Rojas‐Castro, et al.
Veröffentlicht: (2025)

Cross‐Reactive Antibody Responses to Coronaviruses Elicited by SARS‐CoV‐2 Infection or Vaccination
von: Richard S. H. Lee, et al.
Veröffentlicht: (2024)

Cost‐Effectiveness Analysis of a Maternal Vaccination Program Against Respiratory Syncytial Virus in Norway
von: Susanne Gerda Værnø, et al.
Veröffentlicht: (2025)

Establishing Epidemic and Intensity Thresholds After a Major Change in Respiratory Virus Surveillance in Spain in 2020
von: Ana María Puerto, et al.
Veröffentlicht: (2025)

Risk of COVID‐19 Hospitalization and Protection Associated With mRNA Vaccination Among US Adults With Psychiatric Disorders
von: Matthew E. Levy, et al.
Veröffentlicht: (2024)